Development, optimization, and scale-up of suspension Vero cell culture process for high titer production of oncolytic herpes simplex virus-1.
herpes simplex virus
oncolytic viruses
perfusion culture
suspension Vero cell
Journal
Biotechnology journal
ISSN: 1860-7314
Titre abrégé: Biotechnol J
Pays: Germany
ID NLM: 101265833
Informations de publication
Date de publication:
28 Sep 2023
28 Sep 2023
Historique:
revised:
20
07
2023
received:
25
05
2023
accepted:
26
09
2023
pubmed:
28
9
2023
medline:
28
9
2023
entrez:
28
9
2023
Statut:
aheadofprint
Résumé
Oncolytic viruses (OVs) have emerged as a novel cancer treatment modality, and four OVs have been approved for cancer immunotherapy. However, high-yield and cost-effective production processes remain to be developed for most OVs. Here suspension-adapted Vero cell culture processes were developed for high titer production of an OV model, herpes simplex virus type 1 (HSV-1). Our study showed the HSV-1 productivity was significantly affected by multiplicity of infection, cell density, and nutritional supplies. Cell culture conditions were first optimized in shake flask experiments and then scaled up to 3 L bioreactors for virus production under batch and perfusion modes. A titer of 2.7 × 10
Identifiants
pubmed: 37767876
doi: 10.1002/biot.202300244
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2300244Informations de copyright
© 2023 Wiley-VCH GmbH.
Références
Rahman, M. M., & McFadden, G. (2021). Oncolytic ciruses: Newest frontier for cancer immunotherapy. Cancers, 13(21), 5452. https://doi.org/10.3390/cancers13215452
Su, Y., Su, C., & Qin, L. (2022). Current landscape and perspective of oncolytic viruses and their combination therapies. Translational Oncology, 25, 101530. https://doi.org/10.1016/j.tranon.2022.101530
Aldrak, N., Alsaab, S., Algethami, A., Bhere, D., Wakimoto, H., Shah, K., Alomary, M. N., & Zaidan, N. (2021). Oncolytic herpes simplex virus-based therapies for cancer. Cells, 10(6), 1541. https://doi.org/10.3390/cells10061541
Santos Apolonio, J., Lima de Souza Gonçalves, V., Cordeiro Santos, M. L., Silva Luz, M., Silva Souza, J. V., Rocha Pinheiro, S. L., de Souza, W. R., Sande Loureiro, M., & de Melo, F. F. (2021). Oncolytic virus therapy in cancer: A current review. World Journal of Virology, 10(5), 229-255. https://doi.org/10.5501/wjv.v10.i5.229
Mody, P. H., Pathak, S., Hanson, L. K., & Spencer, J. V. (2020). Herpes simplex virus: A versatile tool for insights into evolution, gene delivery, and tumor immunotherapy. Virology: Research and Treatment, 11, 1178122X20913274. https://doi.org/10.1177/1178122X20913274
Menotti, L., & Avitabile, E. (2020). Herpes simplex virus oncolytic immunovirotherapy: The blossoming branch of multimodal therapy. International Journal of Molecular Sciences, 21(21), 8310. https://doi.org/10.3390/ijms21218310
Raman, S. S., Hecht, J. R., & Chan, E. (2019). Talimogene laherparepvec: Review of its mechanism of action and clinical efficacy and safety. Immunotherapy, 11(8), 705-723. https://doi.org/10.2217/imt-2019-0033
Sugawara, K., Iwai, M., Ito, H., Tanaka, M., Seto, Y., & Todo, T. (2021). Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation. Molecular Therapy Oncolytics, 22, 129-142. https://doi.org/10.1016/j.omto.2021.05.004
Russell, S. J., Bell, J. C., Engeland, C. E., & McFadden, G. (2022). Advances in oncolytic virotherapy. Communications Medicine, 2, 33. https://doi.org/10.1038/s43856-022-00098-4
Kiesslich, S., & Kamen, A. A. (2020). Vero cell upstream bioprocess development for the production of viral vectors and vaccines. Biotechnology Advances, 44, 107608. https://doi.org/10.1016/j.biotechadv.2020.107608
Baghirzade, R. (2021). Adherent versus suspensionbased platforms: what is the near future of viral vector manufacturing? Cell & Gene Therapy Insights, 7(11), 1365-1371. https://doi.org/10.18609/cgti.2021.180
Ozuer, A., Wechuck, J. B., Russell, B., Wolfe, D., Goins, W. F., Glorioso, J. C., & Ataai, M. M. (2002). Evaluation of infection parameters in the production of replication-defective HSV-1 viral vectors. Biotechnology Progress, 18(3), 476-482. https://doi.org/10.1021/bp010176k
Ozuer, A., Wechuck, J. B., Goins, W. F., Wolfe, D., Glorioso, J. C., & Ataai, M. M. (2002). Effect of genetic background and culture conditions on the production of herpesvirus-based gene therapy vectors. Biotechnology and Bioengineering, 77(6), 685-692. https://doi.org/10.1002/bit.10162
Wechuck, J. B., Ozuer, A., Goins, W. F., Wolfe, D., Oligino, T., Glorioso, J. C., & Ataai, M. M. (2002). Effect of temperature, medium composition, and cell passage on production of herpes-based viral vectors. Biotechnology and Bioengineering, 79(1), 112-119. https://doi.org/10.1002/bit.10310
O'Keeffe, R., Johnston, M. D., & Slater, N. K. (1998). The primary production of an infectious recombinant Herpes Simplex Virus vaccine. Biotechnology and Bioengineering, 57(3), 262-271. https://doi.org/10.1002/(sici)1097-0290(19980205)57:3<262::aid-bit2>3.0.co;2-f
Knop, D. R., & Harrell, H. (2007). Bioreactor production of recombinant herpes simplex virus vectors. Biotechnology Progress, 23(3), 715-721. https://doi.org/10.1021/bp060373p
Litwin, J. (1992). The growth of Vero cells in suspension as cell-aggregates in serum-free media. Cytotechnology, 10(2), 169-174. https://doi.org/10.1007/BF00570893
Rourou, S., Ben Zakkour, M., & Kallel, H. (2019). Adaptation of Vero cells to suspension growth for rabies virus production in different serum free media. Vaccine, 37(47), 6987-6995. https://doi.org/10.1016/j.vaccine.2019.05.092
Shen, C. F., Guilbault, C., Li, X., Elahi, S. M., Ansorge, S., Kamen, A., & Gilbert, R. (2019). Development of suspension adapted Vero cell culture process technology for production of viral vaccines. Vaccine, 37(47), 6996-7002. https://doi.org/10.1016/j.vaccine.2019.07.003
LaBarre, D. D., & Lowy, R. J. (2001). Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays. Journal of Virological Methods, 96(2), 107-126. https://doi.org/10.1016/s0166-0934(01)00316-0
Valkama, A. J., Leinonen, H. M., Lipponen, E. M., Turkki, V., Malinen, J., Heikura, T., Ylä-Herttuala, S., & Lesch, H. P. (2018). Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor. Gene Therapy, 25(1), 39-46. https://doi.org/10.1038/gt.2017.91
Nam, E. J., & Park, P. W. (2012). Shedding of cell membrane-bound proteoglycans. Methods in Molecular Biology (Clifton, N.J.), 836, 291-305. https://doi.org/10.1007/978-1-61779-498-8_19
Cagno, V., Tseligka, E. D., Jones, S. T., & Tapparel, C. (2019). Heparan sulfate proteoglycans and viral attachment: True receptors or adaptation bias? Viruses, 11(7), 596. https://doi.org/10.3390/v11070596
Akhtar, J., & Shukla, D. (2009). Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. The FEBS Journal, 276(24), 7228-7236. https://doi.org/10.1111/j.1742-4658.2009.07402.x
Spear, P. G., Shieh, M. T., Herold, B. C., WuDunn, D., & Koshy, T. I. (1992). Heparan sulfate glycosaminoglycans as primary cell surface receptors for herpes simplex virus. Advances in Experimental Medicine and Biology, 313, 341-353. https://doi.org/10.1007/978-1-4899-2444-5_33
Shen, C. F., Tremblay, S., Sabourin-Poirier, C., Burney, E., Broussau, S., Manceur, A., Rodenbrock, A., Voyer, R., Loignon, M., Ansorge, S., & Gilbert, R. (2022). Culture media selection and feeding strategy for high titer production of a lentiviral vector by stable producer clones cultivated at high cell density. Bioprocess and Biosystems Engineering, 45(8), 1267-1280. https://doi.org/10.1007/s00449-022-02737-5
Tapia, F., Vázquez-Ramírez, D., Genzel, Y., & Reichl, U. (2016). Bioreactors for high cell density and continuous multi-stage cultivations: Options for process intensification in cell culture-based viral vaccine production. Applied Microbiology and Biotechnology, 100(5), 2121-2132. https://doi.org/10.1007/s00253-015-7267-9
Vázquez-Ramírez, D., Jordan, I., Sandig, V., Genzel, Y., & Reichl, U. (2019). High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system. Applied Microbiology and Biotechnology, 103(7), 3025-3035. https://doi.org/10.1007/s00253-019-09694-2
Hein, M. D., Chawla, A., Cattaneo, M., Kupke, S. Y., Genzel, Y., & Reichl, U. (2021). Cell culture-based production of defective interfering influenza A virus particles in perfusion mode using an alternating tangential flow filtration system. Applied Microbiology and Biotechnology, 105(19), 7251-7264. https://doi.org/10.1007/s00253-021-11561-y
Kamen, A., & Henry, O. (2004). Development and optimization of an adenovirus production process. The Journal of Gene Medicine, 6(Suppl 1), S184-S192. https://doi.org/10.1002/jgm.503
Fulber, J. P. C., Farnós, O., Kiesslich, S., Yang, Z., Dash, S., Susta, L., Wootton, S. K., & Kamen, A. A. (2021). Process development for newcastle disease virus-vectored vaccines in serum-free Vero cell suspension cultures. Vaccines, 9(11), 1335. https://doi.org/10.3390/vaccines9111335